258 results on '"Post, Leonard"'
Search Results
2. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
3. Figure S5 from CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
4. Table S1 from CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
5. Data from CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
6. Applications of Insect Cell Gene Expression in Pharmaceutical Research
7. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
8. Figure S1 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
9. Table S2 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
10. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
11. 516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3+/CD47+tumors
12. CD38 x ICAM-1 Bispecific Antibody is a Novel Approach for Treating Multiple Myeloma and Lymphoma
13. Case History: Talzenna® (Talazoparib)—A Highly Potent, Orally Efficacious PARP Inhibitor for the Treatment of BRCA-Mutated, HER2-Negative Breast Cancer Patients
14. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription
15. Supplementary Data from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
16. Supplementary Tables from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
17. Data from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
18. Abstract B009: TEAD inhibition overcomes YAP1/TAZ-driven resistance to RAS inhibitors in KRASG12C-mutant cancers
19. Abstract 1870: VBI-003, a CD47xEpCAM bispecific antibody as a potential treatment for colorectal and small cell lung cancers
20. Supplementary Figures 1 - 3 from BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
21. Supplementary Figure Legend, Tables 1 - 6 from BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
22. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma
23. Abstract 3430: CD47 x ICAM-1 bispecific antibody represents a novel approach for treating ICAM-1 overexpressing tumors
24. Abstract 5385: Multiple modes of action of the CD38 x ICAM-1 bispecific antibody
25. Abstract 5364: The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models
26. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
27. Nucleotide Sequence of the Ribosomal Protein Gene Cluster adjacent to the Gene for RNA Polymerase Subunit β in Escherichia coli
28. Cloning of Reiterated and Nonreiterated Herpes Simplex Virus 1 Sequences as BamHI Fragments
29. Feedback Regulation of Ribosomal Protein Gene Expression in Escherichia coli: Structural Homology of Ribosomal RNA and Ribosomal Protein mRNA
30. Requirement for the 3 ′ Flanking Region of the Bovine Growth Hormone Gene for Accurate Polyadenylylation
31. CD38 x ICAM1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
32. 274 CD47 x EpCAM bispecific antibody represents a novel approach for treating EpCAM overexpressing solid tumors
33. A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer
34. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin
35. Tumor-specific intravenous gene delivery using oncolytic adenoviruses
36. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth ofNF2-deficient Mesothelioma
37. Abstract 6384: TEAD inhibition reduces tumor proliferation in Merlin null meningioma and schwannoma
38. Abstract PR07: Targeting the Hippo-YAP pathway with small-molecule compounds
39. Selectively Replicating Adenoviruses
40. Chapter 23. Gene Therapy: Progress, New Directions, and Issues
41. Abstract 2886: The Hippo pathway protein YAP mediates resistance to MEK1/2 inhibition in neuroblastoma
42. Abstract 2693: Targeting the Hippo-YAP pathway with novel small-molecule inhibitors of the YAP-TEAD transcription activity
43. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
44. Modern Day Robin Hoods?
45. 'CSI Effect' On Crooks Give Prosecutors Fits
46. Court Urged To Fulfill Crawford Promise
47. High court may clarify use of out-of-court testimony
48. Beam Me Up: High-tech gadgets add flair to trials
49. High-tech gadgets add flair to trials
50. State Chief Justices Discuss New Threats At Annual Meeting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.